Biocon's Syngene

Deal with Zoetis could be worth $500 mn in 10 yrs: Syngene In'l chief

In a Q&A, Jonathan Hunt, MD & CEO of the Biocon arm, dwells on his firm's initiatives to overcome supply chain bottlenecks and other issues

Syngene International signs 10-year agreement with US-based firm Zoetis

Librela or bedinvetmab has already been launched in Europe and the UK, and has won 'Best new companion animal product' by IHS Markit Connect in 2021

Biocon arm Syngene ends contract with Bioinnovat Research over graft case

Guljit Sethi of Bioinnovat was named in CBI FIR on a bribery case involving CDSCO official and Biocon Biologics executive

Covid-19: Biocon's Syngene partners with HiMedia Labs for Elisa test kits

These test kits, developed indigenously, test the presence of SARS-COV-2 antibodies and confirm if a patient has been exposed to the coronavirus

Biocon's Syngene inks pact with GSK for new drug discovery

Biocon's contract research arm Syngene International today said it has inked a drug discovery agreement with global drug firm GSK. The multi-year R&D agreement between the two companies will focus on accelerating the discovery of new drug candidates using Syngene's discovery services platforms, Syngene International said in a regulatory filing. As part of the collaboration, Syngene will set-up a customised discovery research laboratory to support projects across several therapeutic areas, it added. A team of Syngene scientists will work closely with GSK's global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world's most pressing healthcare needs. "The collaboration in many ways underlines Syngene's position as one of the most innovative, capable and cost effective providers of discovery research services to the global pharma industry," Syngene International Chief Executive Officer Jonathan Hunt said. Syngene .